ArticleCureus2023
Cardiovascular Complications of COVID-19: A Scoping Review of Evidence.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Changes in Subclinical Biomarkers of Myocardial Injury and Inflammation and SARS-COV-2 Serological Analyses in a Cohort of Community-dwelling Adults.Research square · 2026Article
- The 3C dataset: A comprehensive dataset for COVID-19 cardiac complications diagnosis.Data in brief · 2026Article
- Long-term cardiovascular impact of COVID-19 among hospitalised and non-hospitalised populations: a narrative synthesis review.Frontiers in cardiovascular medicine · 2026Review
- Artificial Intelligence in Cardiovascular Health: Insights into Post-COVID Public Health Challenges.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2025Review
- Cardiac symptoms in patients 3-6 months after contracting COVID-19- data from the polish STOP-COVID registry.BMC infectious diseases · 2025Observational
- Navigating Cardiovascular Challenges of Obesity: Exploring Preventive Approaches.Endocrine, metabolic & immune disorders drug targets · 2025Review
- The correlation between serum levels of laminin, type IV collagen, type III procollagen N-terminal peptide and hyaluronic acid with the progression of post-COVID-19 pulmonary fibrosis.Frontiers in cell and developmental biology · 2024Article
- Changes in miRNA Pattern Expression Associated With COVID-19 Severity.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This scoping review sought to identify the nature and extent of clinical evidence regarding the acute and long-term cardiovascular complications associated with COVID-19. Forty-nine studies published between 2020 and 2023 were selected for review. The studies were divided into two groups. The referential group included 22 studies. The second group of 27 studies was used for a detailed review to assess the strength of the evidence. The aggregate evidence indicates that the most common cardiac complications associated with COVID-19 include but are not limited to acute pericarditis, acute myocardial injury, acute myocarditis, various arrhythmias, microvascular angiopathy, left ventricular dysfunction, heart failure, acute cardiac injury, and acute coronary syndrome. Clinical and epidemiological implications of the findings are investigated, and future research recommendations are proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.